DATA PAGE

Academic-industry partnerships 2013

Brady Huggett

Public-private partnerships shrank to 301 deals in 2013, down one-fifth from the year prior. Cancer again predominated (84 deals), with neurology (35 deals) and infectious disease (34 deals) second and third in the rankings (Fig. 1). Harvard University was the most active deal maker (Table 1),

but both Johns Hopkins University and KU Leuven broke into the top 5 in 2013. AstraZeneca was the most active pharmaceutical firm (14 deals), whereas GlaxoSmithKline fell from its zenith of 14 deals in 2012 to just 9 last year (Fig. 2).

Table 1 Academic-private partnerships 2013

University	Partners	Focus	Terms
Harvard (7 deals)	Genia Technologies, Columbia University	Genomics	\$5.3 million, US National Human Genome Research Institute grant for nanoTag sequencing
	Evotec	Infectious	Develop small molecule inhibitors of peptidoglycan biosynthesis. Evotec holds drug rights
	Ipsen Group	Neurology	Undisclosed upfront payments, plus potential milestones, royalties to Harvard for recombinant botulinum toxins in neurology diseases
	Evotec	ALS	Partnership with Harvard Stem Cell Institute for preventing or slowing motor neuron loss
	Evotec	Endocrine/Metabolic	Partnership to identify enteroendocrine mechanisms for diabetes therapies
	Army's Edgewood Chemical Biological Center	Microfluidics	Partnership to advance organ-on-a-chip research
University of California System (7 deals)	AstraZeneca	ADMET	Deal with Wyss Institute for Biologically Inspired Engineering for animal-cell versions of institute's organs-on-chips
	UC Davis, Autism Speaks, Baylor College of Medicine, Boston Children's Hospital	Autism	Academic groups join Autism Speaks' Preclinical Autism Consortium for Therapeutics
	UCSF, Genetic Alliance, InVita	Breast Cancer	Formed Free the Data! initiative, to deposit genetic data on breast cancer in databases
	UCLA, NanoSmart Pharmaceuticals	Cancer	Deal on NanoSmart's drug delivery platform for cancer, other pediatric diseases
	UCSF, Onyx Pharmaceuticals	Cancer	Expanded the Oncology Innovation Alliance to investigate hematologic cancers, solid tumors
	UCSF, Pfizer	Disease agnostic	Expanded 2010 partnership to include small molecules. UCSF eligible for milestones, royalties
Johns Hopkins University (5 deals)	UCSF, NeoStem	Diabetes; asthma; organ transplant rejection	Company's expanded 'Tregs' to be tested for diabetes, allo-specific Tregs for organ transplant tolerance. UCSF could receive milestones, royalties
	UCLA, QR Pharma	Nerve damage	\$3 million, US Army grant to test company's Posiphen in rats for traumatic brain injury
	Advanced Cell Diagnostics	Cancer (head and neck)	Deal with Sidney Kimmel Comprehensive Cancer Center to use company's RNAscope platform
	Aduro BioTech	Cancer (melanoma)	Combine Aduro's vaccine technologies with school's non-human anti-programmed cell death 1 ligand
	Gen9	Genomics	Company's BioFab platform will be used in the university's Synthetic Yeast Project Sc2.0
	BioHealth Innovation, DreamIt Ventures	Startups	Launched DreamIt Health Baltimore. 10 health IT startups will receive up to \$50,000 for an 8% equity stake
KU Leuven (3 deals)	AstraZeneca's Medimmune Project	Pharmaceuticals	Five-year, \$6.5 million deal using MedImmune's biologics, AstraZeneca's small molecules
	FIT Biotech Oyj	Cancer, Infectious	Partnership to develop immunotherapies based on FIT Biotech's gene transport unit technology
	Wellcome Trust, Janssen/Johnson & Johnson	Infectious	Partnership to discover and develop antivirals for dengue virus
University of Texas System (3 deals)	Johnson & Johnson	Neurology	Launched Stellar, a five-year collaboration on diagnostics, therapeutics for neurodegenerative diseases
	GlaxoSmithKline, Gustave Roussy, Memorial Sloan-Kettering Cancer Center, Netherlands Cancer Institute, Princess Margaret Cancer Center, University of Texas MD Anderson Cancer Center, Vall d'Hebron Institute of Oncology	Cancer	Group formed the Oncology Clinical and Translational Consortium (OCTC) to investigate GSK's early stage cancer pipeline
	Illumina, Intel, Oregon Health & Science University, Leukemia & Lymphoma Society, Stanford University, University of Texas Southwestern Medical Center, University of Utah	Cancer	The society committed more than \$8.2 million to the Beat AML cancer research initiative
	University of Texas MD Anderson Cancer Center, Amofix Life Sciences	Cancer	Parties formed deal to research misfolded proteins and identify targets for lung cancer drugs

Baylor College of Medicine, McGill University, Stanford, University of Montreal, Vanderbilt University: three deals apiece. Source: SciBX: Science-Business eXchange

First Rounders Podcast: Michael West

West was the first CEO for Geron, which he founded in 1990. He was also CEO of Advanced Cell Technology and is now CEO of BioTime. *Nature Biotechnology* talked to him about his initial love for physics, scoring the first funding for Geron and the future of regenerative medicine.

<http://www.nature.com/nbt/podcast/index.html>

Brady Huggett is Business Editor, *Nature Biotechnology*